The following is a summary of the Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript:
Financial Performance:
Innate Pharma reported cash, cash equivalents, short-term investments and financial assets amounting to EUR 102.3 million at the end of 2023, and an additional EUR 15 million payment received from Sanofi in January 2024.
Revenue and other income from continuing operations totaled EUR 61.6 million in 2023, with operational expenses for the same period at EUR 74.3 million, 75% of which constitutes R&D expenses.
Business Progress:
Innate Pharma continues its late-stage developmental work with Lacutamab, targeting T cell lymphoma and is gathering data for mycosis fungoides.
Effort is being put into expanding the ANKET and Antibody Drug Conjugates (ADCs) portfolio, including licensed assets.
Innate's proprietary first in class NK cell engager platform now has differentiated ADC candidates, with their lead program, IPH45, targeting B-cell non-Hodgkin's lymphoma.
Sanofi has licensed 4 molecules from Innate, two of which are currently in the clinic.
Innate is exploring partnership opportunities for lacutamab's development for Cutaneous T-cell Lymphoma (CTCL).
Future plans include presentations at the ACR for ADC, OCD and IPH45 and project funding is secure till end of 2025.
More details: Innate Pharma IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.